You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 215 AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to β1 integrin

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Checkpoint blockade therapy
215 AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to β1 integrin

 

Online download statistics by month:

Online download statistics by month: November 2020 to August 2024

AbstractFullPdf
Nov 2020147012
Dec 20201203
Jan 20212404
Feb 20212203
Mar 20215908
Apr 202152011
May 20211009
Jun 20210012
Jul 2021008
Aug 20211015
Sep 20211010
Oct 202120014
Nov 202162022
Dec 20214010
Jan 20222207
Feb 202247013
Mar 202230012
Apr 20225208
May 202236016
Jun 20222303
Jul 20223007
Aug 20222003
Sep 20221506
Oct 20221803
Nov 20222202
Dec 20222303
Jan 20232803
Feb 20231607
Mar 20231804
Apr 20231001
May 20232206
Jun 20231202
Jul 20232602
Aug 20232605
Sep 20231002
Oct 20233207
Nov 20231804
Dec 20233801
Jan 20242804
Feb 20242400
Mar 202416015
Apr 202422012
May 20242804
Jun 20243003
Jul 20242805
Aug 20241005
Total11940316